Ibáñez, M. Dolores
Rodríguez del Río, Pablo
González-Segura Alsina, Diego
Villegas Iglesias, Vicenç
Funding for this research was provided by:
Chiesi Spain S.A.U.
Article History
Received: 10 April 2018
Revised: 12 September 2018
Accepted: 12 September 2018
First Online: 26 September 2018
Compliance with ethical standards
: The study was conducted in accordance with the Declaration of Helsinki (7th revision), the Spanish regulations on observational studies (Order SAS 3470/2009) and Spanish personal data protection law (Law 15/1999). The study protocol was approved by the Ethics Committee of Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Parents or legal representatives of all patients gave written informed consent before inclusion. All data were anonymized.
: MDI received research funding from the Health Research Fund of the Carlos III Health Institute, and from Aimmune Therapeutics; serves as a consultant for Merk, Novartis, and Chiesi Spain; and has received payments for lectures from the Spanish Society of Allergology and Clinical Immunology, Leti Pharma, Merck, FAES Pharma, and MSD.PRR received research funding from the Health Research Fund of Carlos III Health Institute, the Foundation for Biomedical Research of the Niño Jesús University Children’s Hospital, the Spanish Society of Allergology, and the Clinical Immunology Foundation. He received honoraria for consultancy and/or advisory board and/or lectures from ALK-Abelló, HAL-Allergy, FAES Pharma, LETI Pharma, Merck, Aimmune Therapeutics, Allergy Therapeutics, MEDA Pharma, and Novartis.DGA and VVI are employees of Chiesi Spain.
: Parents or legal representatives of all patients included in the study gave written informed consent before inclusion.